Interesting that this broker appears to see negatives concerning ACR, wouldn't be the first time I understand. I guess their report underlines why I would expect ACR management to highlight what the Eli Lilly quarterly sales figure is about. My reading is the Eli Lilly report indicates growth is heading in the right direction which surprises me that Macquarie have an underperform rating. Well I guess if today's rally continues, there will be egg on either my face or a certain broker.
ACR Price at posting:
$3.60 Sentiment: Buy Disclosure: Held
